Michel  Vounatsos net worth and biography

Michel Vounatsos Biography and Net Worth

CEO of Biogen
Michel Vounatsos is Chief Executive Officer at Biogen and has served as a director since January 2017. As CEO, his time has been spent strategically bolstering Biogen as a worldwide pioneer in neuroscience and adjacent therapeutic areas, positioning the company for long-term growth through a multi-franchise portfolio.  

He brings comprehensive global leadership expertise resulting from decades of service as an executive in the pharmaceutical industry, as well as a unique academic perspective from his time studying both medicine and business. He joined Biogen as Executive Vice President & Chief Commercial Officer in April 2016, holding that role until his promotion to CEO. Prior to that, he had a 20-year career at Merck, where he worked in diverse markets globally, including China, France, and Poland. His last role at Merck was President, Primary Care and Customer Centricity in the United States. During his tenure at Merck, he helped transform its go-to-market model and further expanded its business in mature and emerging markets. Previously, he held management positions at Ciba-Geigy AG, a pharmaceutical company.  

He is a director of PerkinElmer, Inc., a global scientific technology and life science research company. He serves on the advisory board of China’s Tsinghua University School of Pharmaceutical Sciences; the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, France; and as a member of the MIT Presidential CEO Advisory Board. He is on the board of directors at the U.K.’s Early Detection of Neurodegenerative Diseases (EDoN). Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Université Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

What is Michel Vounatsos' net worth?

The estimated net worth of Michel Vounatsos is at least $1.07 million as of December 29th, 2017. Mr. Vounatsos owns 4,879 shares of Biogen stock worth more than $1,070,453 as of March 18th. This net worth approximation does not reflect any other investments that Mr. Vounatsos may own. Learn More about Michel Vounatsos' net worth.

How do I contact Michel Vounatsos?

The corporate mailing address for Mr. Vounatsos and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Michel Vounatsos' contact information.

Has Michel Vounatsos been buying or selling shares of Biogen?

Michel Vounatsos has not been actively trading shares of Biogen within the last three months. Most recently, on Monday, November 30th, Michel Vounatsos bought 3,100 shares of Biogen stock. The stock was acquired at an average cost of $241.31 per share, with a total value of $748,061.00. Learn More on Michel Vounatsos' trading history.

Who are Biogen's active insiders?

Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.

Are insiders buying or selling shares of Biogen?

During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 9 times. They sold a total of 4,751 shares worth more than $1,331,440.62. The most recent insider tranaction occured on February, 22nd when insider Priya Singhal sold 262 shares worth more than $57,962.26. Insiders at Biogen own 0.6% of the company. Learn More about insider trades at Biogen.

Information on this page was last updated on 2/22/2024.

Michel Vounatsos Insider Trading History at Biogen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2020Buy3,100$241.31$748,061.00View SEC Filing Icon  
5/1/2019Buy4,351$231.48$1,007,169.48View SEC Filing Icon  
12/29/2017Buy780$320.55$250,029.00View SEC Filing Icon  
12/29/2017Buy780$320.55$250,029.004,879View SEC Filing Icon  
5/1/2017Buy1,402$271.35$380,432.70View SEC Filing Icon  
2/27/2017Buy1,333$285.39$380,424.87View SEC Filing Icon  
See Full Table

Michel Vounatsos Buying and Selling Activity at Biogen

This chart shows Michel Vounatsos's buying and selling at Biogen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biogen Company Overview

Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $219.40
Low: $217.64
High: $220.56

50 Day Range

MA: $234.20
Low: $216.99
High: $255.84

2 Week Range

Now: $219.40
Low: $215.35
High: $319.76

Volume

1,356,515 shs

Average Volume

1,170,348 shs

Market Capitalization

$31.89 billion

P/E Ratio

27.49

Dividend Yield

N/A

Beta

N/A